T. Geldart

1.2k citations

40 papers · 642 indexed · h-index 15

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Immunology
- Immunotherapy and Immune Responses

Papers in

Oncology 20
- Lung Cancer Research Studies 5
- CAR-T cell therapy research 4
Pulmonary and Respiratory Medicine 23
- Renal cell carcinoma treatment 9
- Lung Cancer Treatments and Mutations 7

Co-authors: Matthew Wheater Graham M. Mead Simon J. Crabb Peter Johnson Christian H. Ottensmeier Tim Illidge Esther Uña Cidón S. W. Ellis
Journals: Annals of Oncology (10 papers)Journal of Clinical Oncology (10 papers)Journal of Thoracic Oncology (2 papers)Clinical Radiology (2 papers)Lung Cancer (2 papers)
Partner nations: United Kingdom Switzerland India

In The Last Decade

T. Geldart

37 papers receiving 633 citations

Peers

Countries citing papers authored by T. Geldart

Since Specialization

Citations

This map shows the geographic impact of T. Geldart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Geldart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Geldart more than expected).

Fields of papers citing papers by T. Geldart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Geldart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Geldart. The network helps show where T. Geldart may publish in the future.

Co-authorship network

The 25 scholars most cited alongside T. Geldart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with T. Geldart Line = papers co-authored together T. Geldart links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	210 If at first you don't succeed…switching treatments in NTRK fusion NSCLC Lung Cancer ·Debbie Scott, T. Geldart	2024	0
2	1457P A UK multicentre retrospective review of metastatic renal cell carcinoma (mRCC) patients (pts) outcomes with brain metastases (BM) in the modern era Annals of Oncology ·Jean Ph, Amarnath Challapalli, John McGrane, 英俊大西, Freiin Von, Soenke Stern, Sarah Kingdon, Anna Lydon, Anand Sharma, Mark Tuthill, Zhong Xu-don, K.A. Haemeen-Anttila, Natalie Charnley, Jahangeer Malik, Menne PM. Scherpenzeel, زينب محمد حسن, T. Geldart, Minghua Liu WENZHEN, Hanky Prince Sereo, Amit Bahl	2022	2
3	1463P Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review Annals of Oncology ·Amarnath Challapalli, Jean Ph, John McGrane, 英俊大西, Freiin Von, Soenke Stern, Sarah Kingdon, Anna Lydon, Anand Sharma, Mark Tuthill, Christopher G. McCusker, Z. Li, N. Vedovotto, Jahangeer Malik, A M Vdovina, Romina Buono, T. Geldart, مریم محمدی ثانی, Jane Brown, Amit Bahl	2022	0
4	1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review Annals of Oncology ·G Ciofalo, Вэньцзяо Чжан, Colin R. Lindsay, Tetiana Solominchuk, M. Button, Nicola Steele, Stefan Heeg, Ana Rosa ARREDONDO, 贾超琴, David Farrugia, JEWEL ANNE G. SALVADOR, N Markov, Alban Chazot, Shobhit Baijal, 焦豪杰, T. Geldart, Quynhmai Tran, Charel Bruwer, Alastair Greystoke, Tom Newsom‐Davis	2022	2
5	1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience Annals of Oncology ·Otto Mohr, J. J Jankowski, Muramatsu Hiroaki, Bengt Arne Roos, Patrice Guirao, GABRIELA DE ALMEIDA CARDOSO, Nicola Steele, Endang Danial, Stephen Robinson, H.Campbell Thomson, E O’Brien, Samantha Cox, Ceri Powell, S. Kabana, T. Geldart, 陈立军, Thomas Newsom-Davis, Tran Duong Duy, Fiona Blackhall, Raffaele Califano	2022	2
6	Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study. Journal of Clinical Oncology ·Pippa Corrie, Sarah J. Welsh, Grant D. Stewart, Gary J. Doherty, Kévin Vervier, Nasrin. Sadidi, Christine Parkinson, Kate Fife, Guy Faust, ZONG-WEI ZHU, T. Geldart, Ewan Brown, Matthew Wheater, Jenny Nobes, David Bruce, Nikos Demiris, Paul E. Van Schil, David J. Adams, 瑛一高沢, Trevor D. Lawley	2021	1
7	P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial) Journal of Thoracic Oncology ·Sanjay Popat, Laura Hughes, Mary O’Brien, Tanya Ahmad, C. Lewanski, U. Dernedde, Petra Jankowska, C Mulatero, Riyaz Shah, Jonathan Hicks, T. Geldart, Kudlacak Frantisek, 朗染川, James Spicer, Karen L. Bell, Yenting Ngai, Allan Hackshaw	2017	3
8	A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) Annals of Oncology ·Thomas Powles, Janet E. Brown, James Larkin, Robert J. Jones, Christy Ralph, Robert D. Hawkins, S. Chowdhury, Ekaterini Boleti, Sumner Thompson, Kate Fife, Andrew Webb, Simon J. Crabb, T. Geldart, Robert Hill, Joanna Dunlop, Peter E. Hall, Duncan B. McLaren, Charlotte Ackerman, Luis Beltrán, Paul Nathan	2016	16
9	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC Journal of Thoracic Oncology ·Edurne Arriola, Matthew Wheater, Ian Galea, S. Aldino, Tom Maishman, 廖宏昌, Louise Stanton, Judith Cave, T. Geldart, C Mulatero, Poh Lyn Teo-Dixon, Sarah Danson, Penella J. Woll, Richard W. Griffiths, Luke Nolan, Christian H. Ottensmeier	2016	97
10	Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience Annals of Oncology ·زينب محمد حسن, Richard Cathomas, Matthew Wheater, Dirk Klingbiel, Martin Fehr, GMontrucchio, Hannah Markham, Vishal Sawarn, Simon J. Crabb, T. Geldart	2015	26
11	Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients European Journal of Cancer Care ·زينب محمد حسن, Matthew Wheater, T. Geldart, Simon J. Crabb	2015	21
12	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer European Urology ·Thomas Powles, Matthew Wheater, Omar Din, T. Geldart, Ekaterini Boleti, Andrew Stockdale, Santhanam Sundar, 苏耀昌, Imtiaz Ahmed, Akhila Wimalasingham, Wendy Burke, Shah‐Jalal Sarker, Syed A. Hussain, Christy Ralph	2015	83
13	SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma European Urology ·T. Geldart, John Chester, Angela Casbard, Simon J. Crabb, Tony Elliott, Andrew Protheroe, Robert Huddart, Graham M. Mead, Jim Barber, Robert J. Jones, Joanna Smith, D. C. DAMIN, Jessica Evans, Gareth Griffiths	2014	27
14	Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract British Journal of Cancer ·James J. Douglas, Adam Sharp, زينب محمد حسن, Julia E. Head, E. Doyle, Matthew Wheater, T. Geldart, Graham M. Mead, Simon J. Crabb	2014	23
15	Bladder carcinoma recurrence post-cystectomy simulating rectal carcinoma Clinical Radiology ·D. V. Khodakova, J. Smart, T. Geldart, Cornelius Zhao, Ken Tung	2007	2
16	Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure British Journal of Urology ·T. Geldart, Joanna Gale, J. McKendrick, G. Iannaccone, Bikas Singha Mahapatra	2006	29
17	Late relapse of metastatic non-seminomatous testicular germ cell tumours Clinical Radiology ·Elaine Rutherford, Jason L. Ferguson, T. Geldart, Graham M. Mead, Joanne Smart, Ken Tung	2006	4
18	The Combination of Raltitrexed (Tomudex) and Mitomycin-C in the Treatment of Advanced Colorectal Cancer — A Phase II Study Clinical Oncology ·Jorg Michels, T. Geldart, Issac Almasi, Gauléjac, A Iveson, Laura A. Richardson, Timothy Iveson	2006	1
19	Anti-CD40 monoclonal antibody Leukemia & lymphoma ·T. Geldart, Tim Illidge	2005	15
20	Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer British Journal of Urology ·T. Geldart, P.D. Simmonds, Graham M. Mead	2002	20

About T. Geldart

T. Geldart is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Urology and Nephrology, having authored 40 papers that have together received 642 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (9 papers), Testicular diseases and treatments (7 papers), Bladder and Urothelial Cancer Treatments (7 papers), Lung Cancer Treatments and Mutations (7 papers), Urinary and Genital Oncology Studies (6 papers), Lung Cancer Research Studies (5 papers), CAR-T cell therapy research (4 papers) and Renal and related cancers (4 papers). The work is most often cited by research in Oncology (293 citations), Immunology (122 citations), Pulmonary and Respiratory Medicine (178 citations), Surgery (211 citations) and Reproductive Medicine (40 citations). T. Geldart has collaborated with scholars based in United Kingdom, Switzerland and India. Frequent co-authors include Matthew Wheater, Graham M. Mead, Simon J. Crabb, Peter Johnson, Christian H. Ottensmeier, Tim Illidge, Esther Uña Cidón, S. W. Ellis, Sola Adeleke and Judith Cave. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Radiology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact